The VAX-31 pneumococcal conjugate vaccine (PCV) candidate met all prespecified primary endpoints in OPUS-1, the pivotal adult phase 3 trial, according to the vaccine’s manufactu ...
Pivotal adult trial data support planned BLA submission for Vaxcyte's investigational 31-valent pneumococcal conjugate ...
In May 2025, the FDA expanded the Breakthrough Therapy designation (BTD) for VAX-31 to include the prevention of pneumonia caused by Streptococcus pneumoniae in addition to the prevention of IPD in ...
Tower Transit has acquired PCV driver training business Abacus UK Training of Huyton. It builds on the earlier integration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results